The Food and Drug Administration has approved Kisunla, a new Alzheimer’s drug from the drugmaker Eli Lilly, the company announced on Tuesday.

The drug modestly slowed memory decline in Alzheimer’s patients during clinical trials, according to the drugmaker.

The drug targets amyloid in the brain to fight the disease. It's now approved for use in patients with early Alzheimer’s disease.

Kisunla is currently in the form of monoclonal antibody infusion that's administered every four weeks.